Growth hormone therapy in pediatrics

Więcej o książce

For 20 years, KIGS has been a vital tool for monitoring growth hormone (GH) treatment in children with short stature from various origins. This volume updates the ongoing experiences in KIGS, drawing on data from over 50 countries and more than 60,000 patients. International experts analyze the auxological characteristics of patients and their responses to GH treatment for a wide range of growth disorders, including idiopathic GH deficiency, organic GH deficiency from congenital malformations, genetic disorders, and short stature in children born small for gestational age. Each disorder is reviewed with relevant published data by specialists. KIGS also serves as a primary source for information on adverse events during long-term GH treatment, revealing no new adverse drug reactions in the last decade, suggesting that GH treatment is low-risk for affected children and adolescents. The development of disease-specific growth response prediction models has been a focus, with existing models showing accuracy and precision, although further predictors are still needed. These models can be prospectively applied to new patients, improving the tailoring and monitoring of GH therapy for optimal outcomes. The future of KIGS relies on the quality of reported data and the commitment of participating physicians, emphasizing the importance of valid safety and efficacy information in pediatric endocrinology through this international collabor